ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Accounts Payable

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) posts a accounts payable of $10B as of March 2026. That compares with $9.6B in the prior-year period — up 6.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s accounts payable was $9.6B. The latest reading is $10B — a 6.6% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s financial statement story. At $10B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LSPRU's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s other metric pages and overview cover the third.